| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7963e24dd807df9623be5e58b417f352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37549e0727671e86ec014524c6fc6992
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e3b567c1e744c006a14cc0de082e681 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-43504
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate |
2011-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d41de2e6b5370cac87dd675db025838b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fb3e12d788fd31ad97762d513ad3d3a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f7a372ef78a9f787bae0b17d6d19668
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abc641053c067a50cb9fe91919ed3b78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8581bfe846c339fc23831823fd5ae2a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f83bf552b1fc7c25fc2636671a8a652
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fcac1ffdb8f33a9f22bddc43562b0f6 |
| publicationDate |
2012-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2476441-A1 |
| titleOfInvention |
Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells |
| abstract |
The invention relates to conjugates comprising a targeting moiety specific for the CXCR4 based on the polyphemusin-derived peptide and a therapeutic or imaging agent. The invention relates as well to the application of said conjugates for the therapy and diagnostics which require the specific targeting to CXCR4+ cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3722255-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018202921-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020208065-A1 |
| priorityDate |
2011-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |